This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Alethia BioTherapeutics Inc.
Drug Names(s): AB-25E9
Description: AB-25E9 is a monoclonal antibody that inhibits osteoclast differentiation and bone resorption. It targets Siglec-15, a cell-surface protein specifically expressed on osteoclasts.
Additional information available to subscribers only: